What makes psoriatic and rheumatoid arthritis so different?

RMD Open

Volumn 1, Issue 1, 2015, Pages

  Veale, Douglas James ^a,b   Fearon, Ursula ^a,b  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018193016     PISSN: None     EISSN: 20565933     Source Type: Journal    
DOI: 10.1136/rmdopen-2014-000025     Document Type: Review

References (37)

1. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
2. Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973;32:181-201.
3. Avila R, Pugh DG, Slocumb CH, et al. Psoriatic arthritis: a roentgenologic study. Radiology 1960;75:691-702.
4. Finzel S, Englbrecht M, Engelke K, et al. A comparative study of periarticular bone lesions in rheumatoid arthritis and psoriatic arthritis. Ann Rheum Dis 2011;70:122-7.
5. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum 1999;42:1080-6.
6. Kennedy A, Ng CT, Chang TC, et al. Tumor necrosis factor blocking therapy alters joint inflammation and hypoxia. Arthritis Rheum 2011;63:923-32.
7. Gladman DD, Farewell VT, Rahman P, et al. HLA-DRB1∗04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. Hum Immunol 2001;62:1239-44.
8. Dougados M, Baeten D. Spondyloarthritis. Lancet 2011;377:2127-37.
9. Sherlock JP, Joyce-Shaikh B, Turner SP, et al. IL-23 induces spondyloarthropathy by acting on ROR-gt+CD3+CD4-CD8- entheseal resident T cells. Nat Med 2012;18:1069-76.
10. Espinoza LR, Vasey FB, Espinoza CG, et al. Vascular changes in psoriatic synovium. A light and electron microscopic study. Arthritis Rheum 1982;25:677-84.
11. Veale DJ, Yanni G, Rogers S, et al. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 1993;36:893-900.
12. Fraser A, Fearon U, Reece R, et al. Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum 2001;44:2024-8.
13. Fearon U, Griosios K, Fraser A, et al. Angiopoietins, growth factors, and vascular morphology in early arthritis. J Rheumatol 2003;30:260-8.
14. Yeremenko N, Baeten D. IL-17 in spondyloarthritis: is the T-party over? Arthritis Res Ther 2011;13:115.
15. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-64.
16. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011;63:939-48.
17. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
18. Sanmartí R, Graell E, Perez ML, et al. Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis. Arthritis Res Ther 2009;11:R135.
19. Huynh D, Kavanaugh A. Psoriatic arthritis: current therapy and future approaches. Rheumatology 2015;54:20-8.
20. Kane D, Veale DJ, FitzGerald O, et al. Survey of arthroscopy performed by rheumatologists. Rheumatology 2002;41:210-15.
21. Reece RJ, Canete JD, Parsons WJ, et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-4.
22. Fiocco U, Cozzi L, Chieco-Bianchi F, et al. Vascular changes in psoriatic knee joint synovitis. J Rheumatol 2001;28:2480-6.
23. Salvador G, Sanmartí R, Gil-Torregrosa B, et al. Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis. Rheumatology 2006;45:966-71.
24. Veale DJ, Ritchlin C, FitzGerald O. Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005;64(Suppl 2):iiP9.
25. Cunnane G, Grehan S, Geoghegan S, et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000;27:58-63.
26. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med 2006;3:e297.
27. Saber TP, Ng C, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? Arthritis Res Ther 2010;12:R94.
28. Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum 2011;63:382-90.
29. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebocontrolled study (RAPID-PsA). Ann Rheum Dis 2014;73:48-55.
30. Kane D, Stafford L, Bresnihan B, et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology 2003;42:1460-8.
31. McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780-9.
32. Ritchlin C, Rahman P, Kavanaugh A, et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990-9.
33. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010;2:52ra72.
34. Genovese MC, Durez P, Richards HB. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 2014;41:414-21.
35. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2013;73:349-56.
36. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9.
37. Mease PJ, Genovese MC, Greenwald MW, et al. Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med 2014;370:2295-306.